Meeting
2023 ASCO Genitourinary Cancers Symposium
Impact of systemic therapy (ST) on deferred cytoreductive nephrectomy (CN) perioperative outcomes: A National Surgical Quality Improvement Program (NSQIP) analysis.
Authors
Shawn Dason
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Shawn Dason , Tyler Sheetz , Shagnik Ray , Danielle Elise Zimmerman , Ming Yin , Edmund Folefac , Amir Mortazavi , Michael Gong , Ahmad Shabsigh , Eric A. Singer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 650)
DOI
10.1200/JCO.2023.41.6_suppl.650
Abstract #
650
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Monitoring efficacy of neoadjuvant sunitinib in metastatic renal cell carcinoma using a personalized and tumor informed ctDNA assay.
First Author: Christine B. Peterson
Poster
2022 ASCO Genitourinary Cancers Symposium
The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.
First Author: Abhenil Mittal
Poster
2021 ASCO Annual Meeting
Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
First Author: Pooja Ghatalia
Poster
2021 Genitourinary Cancers Symposium
Prognostic value of simple blood biomarkers of systemic inflammation for metastatic renal cell carcinoma (mRCC) patients who undergo cytoreductive nephrectomy (CNx).
First Author: Jigi Moudgil-Joshi